Lynsey Fazal

Medicine · Health Sciences

13h-index1.2kcitations48works1.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer-related Molecular Pathways(12), Synthesis and biological activity(9), Melanoma and MAPK Pathways(9), Fibroblast Growth Factor Research(7), Microtubule and mitosis dynamics(6)

Publications48 total

Abstract 1627: Switching cell fate from senescence to apoptosis by the combination of a p53 corrector with the MDM2 antagonist ASTX295
Cancer Research·2025
289 (PB277): Pulsatile induction of the p53 pathway by MDM2 antagonist ASTX295 shows an enhanced therapeutic index in vivo
European Journal of Cancer·2024
Abstract 6588: Discovery of ASTX295, a potent, next-generation small molecule antagonist of MDM2 with differentiated pharmacokinetic profile
Cancer Research·2024· 2 cited
Abstract 3333: Targeting the MDM2-p53 interaction: Time- and concentration-dependent studies in tumor and normal human bone marrow cells reveal strategies for an enhanced therapeutic index
Cancer Research·2024· 3 cited
Abstract 667: Identification of biomarkers of response to MDM2 inhibition in solid tumours using computational, multi-omics approaches
Cancer Research·2024
Abstract A110: Identifying sensitive patient populations for CDK7 inhibitors using cell panel screens and bioinformatic approaches
Molecular Cancer Therapeutics·2023
Supplementary Methods, Figures 1-4, Tables 1-2 from Potent, Selective Inhibitors of Fibroblast Growth Factor Receptor Define Fibroblast Growth Factor Dependence in Preclinical Cancer Models
2023Open Access
Data from Potent, Selective Inhibitors of Fibroblast Growth Factor Receptor Define Fibroblast Growth Factor Dependence in Preclinical Cancer Models
2023Open Access
Data from Potent, Selective Inhibitors of Fibroblast Growth Factor Receptor Define Fibroblast Growth Factor Dependence in Preclinical Cancer Models
2023Open Access
Supplementary Methods, Figures 1-4, Tables 1-2 from Potent, Selective Inhibitors of Fibroblast Growth Factor Receptor Define Fibroblast Growth Factor Dependence in Preclinical Cancer Models
2023Open Access
A commentary on the use of pharmacoenhancers in the pharmaceutical industry and the implication for DMPK drug discovery strategies
Xenobiotica·2022· 3 cited
Abstract P112: Treatment with the dual-mechanism ERK inhibitor, ASTX029, alters myeloid cell differentiation
Molecular Cancer Therapeutics·2021
Discovery of ASTX029, A Clinical Candidate Which Modulates the Phosphorylation and Catalytic Activity of ERK1/2
Journal of Medicinal Chemistry·2021· 17 citedOpen Access
Abstract 1661: Immune modulation by the dual-mechanism ERK inhibitor, ASTX029, in MAPK-activated tumor models
Cancer Research·2021
CCDC 2059877: Experimental Crystal Structure Determination
The Cambridge Structural Database·2021Open Access
Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein–Protein Interaction
Journal of Medicinal Chemistry·2021· 52 cited
Anti-Tumor Activity of ASTX029, a Dual Mechanism Inhibitor of ERK1/2, in Preclinical AML Models
Blood·2020· 1 cited
Combined inhibition of SHP2 and ERK enhances anti-tumour effects in preclinical models
European Journal of Cancer·2020
Abstract 3030: Different pharmacodynamic profiles of ERK1/2 inhibition can elicit comparable anti-tumor activity
Cancer Research·2020
PS988 CHARACTERIZATION OF A NOVEL, POTENT SMALL MOLECULE MDM2 ANTAGONIST WHICH ACTIVATES WILD‐TYPE P53 AND INDUCES APOPTOSIS IN AML
HemaSphere·2019Open Access
page 1 of 3Next →

Frequent Co-authors

Neil T. Thompson(22), Nicola E. Wilsher(16), Brent Graham(15), Nicola G. Wallis(15), John F. Lyons(14), Steven Howard(12), Valério Berdini(12), Gianni Chessari(12), Christopher W. Murray(12), Luke Bevan(12), David R. Newell(12), Sharna J. Rich(11), David C. Rees(9), Matthias Reule(9), Ruth E. Feltell(9), Joanne M. Munck(9), Martyn Frederickson(8), Ildiko M. Buck(8), Vanessa Martins(8), Michael Reader(8)